{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:22:11Z","timestamp":1754162531434,"version":"3.41.2"},"reference-count":37,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2025.14999","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T09:05:53Z","timestamp":1743152753000},"page":"1-9","source":"Crossref","is-referenced-by-count":1,"title":["Achieving stringent complete remission in relapsed\/refractory multiple myeloma with liver extramedullary disease after CAR\u2011T cell therapy: A case report"],"prefix":"10.3892","volume":"29","author":[{"given":"Lingyun","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Hematology, Shenzhen Luohu People's Hospital, Shenzhen, Guangdong 518000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danbo","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shenzhen Luohu People's Hospital, Shenzhen, Guangdong 518000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shenzhen Luohu People's Hospital, Shenzhen, Guangdong 518000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiao","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shenzhen Luohu People's Hospital, Shenzhen, Guangdong 518000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenyi","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shenzhen Luohu People's Hospital, Shenzhen, Guangdong 518000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxian","family":"Xiang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shenzhen Luohu People's Hospital, Shenzhen, Guangdong 518000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haifei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shenzhen Luohu People's Hospital, Shenzhen, Guangdong 518000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"key":"key20250730121709_b1-ol-29-5-14999","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1093\/jnci\/djae321","article-title":"The global multiple myeloma incidence and mortality burden in 2022 and predictions for 2045","volume":"117","author":"Mafra","year":"2025","journal-title":"J Natl Cancer Inst"},{"key":"key20250730121709_b2-ol-29-5-14999","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: A prospective, noninterventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"},{"key":"key20250730121709_b3-ol-29-5-14999","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3390\/curroncol32030182","article-title":"Extramedullary multiple myeloma: challenges and opportunities","volume":"32","author":"Ho","year":"2025","journal-title":"Current Oncology"},{"key":"key20250730121709_b4-ol-29-5-14999","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","article-title":"Extramedullary disease in multiple myeloma: a systematic literature review","volume":"12","author":"Blad\u00e9","year":"2022","journal-title":"Blood Cancer J"},{"key":"key20250730121709_b5-ol-29-5-14999","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00262-024-03913-0","article-title":"Targeting BCMA in multiple myeloma: designs, challenges, and future directions","volume":"74","author":"Hu","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"key20250730121709_b6-ol-29-5-14999","doi-asserted-by":"publisher","first-page":"755866","DOI":"10.3389\/fimmu.2021.755866","article-title":"Anti-BCMA CAR-T Cell Therapy in Relapsed\/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials","volume":"12","author":"Que","year":"2021","journal-title":"Frontiers in Immunology"},{"key":"key20250730121709_b7-ol-29-5-14999","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41408-024-01068-w","article-title":"Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy","volume":"14","author":"Dima","year":"2024","journal-title":"Blood Cancer J"},{"key":"key20250730121709_b8-ol-29-5-14999","first-page":"866","article-title":"Chinese Society of Hematology, Chinese Myeloma Committee-Chinese Hematology Association. The guidelines for the diagnosis and management of multiple myeloma in China (2017 revision)","volume":"56","author":"Chinese Hematology Association","year":"2017","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"key20250730121709_b9-ol-29-5-14999","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"key":"key20250730121709_b10-ol-29-5-14999","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20250730121709_b11-ol-29-5-14999","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: A report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"key20250730121709_b12-ol-29-5-14999","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41409-018-0264-8","article-title":"Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: A mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus statement","volume":"54","author":"Gonsalves","year":"2019","journal-title":"Bone Marrow Transplant"},{"author":"National Comprehensive Cancer Network (NCCN)","key":"key20250730121709_b13-ol-29-5-14999","article-title":"NCCN Guidelines Multiple Myeloma"},{"key":"key20250730121709_b14-ol-29-5-14999","doi-asserted-by":"publisher","first-page":"4416","DOI":"10.1200\/JCO.23.00512","article-title":"Chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma: Moving into the future","volume":"41","author":"Holstein","year":"2023","journal-title":"J Clin Oncol"},{"key":"key20250730121709_b15-ol-29-5-14999","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/s41375-021-01471-3","article-title":"Treatment outcomes of triple class refractory multiple myeloma: A benchmark for new therapies","volume":"36","author":"Bal","year":"2022","journal-title":"Leukemia"},{"key":"key20250730121709_b16-ol-29-5-14999","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/s41408-022-00733-2","article-title":"I-OPen: Inferior outcomes of Penta-refractory compared to Penta-exposed multiple myeloma patients","volume":"12","author":"Gill","year":"2022","journal-title":"Blood Cancer J"},{"key":"key20250730121709_b17-ol-29-5-14999","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41408-023-00785-y","article-title":"Defining drug\/drug class refractoriness vs lines of therapy in relapsed\/refractory multiple myeloma","volume":"13","author":"Goel","year":"2023","journal-title":"Blood Cancer J"},{"key":"key20250730121709_b18-ol-29-5-14999","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"key20250730121709_b19-ol-29-5-14999","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"key20250730121709_b20-ol-29-5-14999","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1111\/cas.15556","article-title":"Ciltacabtagene autoleucel in patients with relapsed\/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort","volume":"113","author":"Ri","year":"2022","journal-title":"Cancer Sci"},{"key":"key20250730121709_b21-ol-29-5-14999","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"key20250730121709_b22-ol-29-5-14999","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s12185-023-03538-6","article-title":"Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma","volume":"117","author":"Minakata","year":"2023","journal-title":"Int J Hematol"},{"key":"key20250730121709_b23-ol-29-5-14999","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s12885-023-10824-3","article-title":"Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed\/refractory multiple myeloma patients","volume":"23","author":"Sanoyan","year":"2023","journal-title":"BMC Cancer"},{"article-title":"IASO Bio Presents updated long-term follow-up data for BCMA CAR-T FUCASO\u00ae (Equecabtagene Autoleucel) at IMS 2023","year":"2023","author":"IASO Biotherapeutics","key":"key20250730121709_b24-ol-29-5-14999"},{"key":"key20250730121709_b25-ol-29-5-14999","doi-asserted-by":"publisher","first-page":"S4564","DOI":"10.1182\/blood-2022-168610","article-title":"Phase II study of fully human BCMA-Targeting CAR-T Cells (Zevorcabtagene Autoleucel) in patients with relapsed\/refractory multiple myeloma","volume":"1401","author":"Chen","year":"2022","journal-title":"Blood"},{"key":"key20250730121709_b26-ol-29-5-14999","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1182\/blood.2020008936","article-title":"A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed\/refractory multiple myeloma","volume":"137","author":"Wang","year":"2021","journal-title":"Blood"},{"article-title":"Equecabtagene autoleucel injection approved with conditions by China NMPA","year":"2023","author":"National Medical Products Administration (NMPA)","key":"key20250730121709_b27-ol-29-5-14999"},{"key":"key20250730121709_b28-ol-29-5-14999","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nbt.4195","article-title":"Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo","volume":"36","author":"Rafiq","year":"2018","journal-title":"Nat Biotechnol"},{"key":"key20250730121709_b29-ol-29-5-14999","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.jcyt.2018.07.005","article-title":"Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells","volume":"20","author":"Zolov","year":"2018","journal-title":"Cytotherapy"},{"key":"key20250730121709_b30-ol-29-5-14999","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","article-title":"A combination of humanized anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: A single-arm, phase 2 trial","volume":"6","author":"Yan","year":"2019","journal-title":"Lancet Hematol"},{"key":"key20250730121709_b31-ol-29-5-14999","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/bjh.17338","article-title":"Expert review on soft-tissue plasmacytomas in multiple myeloma: Definition, disease assessment and treatment considerations","volume":"194","author":"Rosi\u00f1ol","year":"2021","journal-title":"Br J Hematol"},{"key":"key20250730121709_b32-ol-29-5-14999","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B-cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"key":"key20250730121709_b33-ol-29-5-14999","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1073\/pnas.1819745116","article-title":"Exploratory trial of a biepitopic CAR T-targeting B-cell maturation antigen in relapsed\/refractory multiple myeloma","volume":"116","author":"Xu","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20250730121709_b34-ol-29-5-14999","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"key20250730121709_b35-ol-29-5-14999","doi-asserted-by":"publisher","first-page":"e346","DOI":"10.1002\/ctm2.346","article-title":"A phase I study of anti-BCMA CAR T-cell therapy in relapsed\/refractory multiple myeloma and plasma cell leukemia","volume":"11","author":"Li","year":"2021","journal-title":"Clin Transl Med"},{"key":"key20250730121709_b36-ol-29-5-14999","doi-asserted-by":"publisher","first-page":"6384","DOI":"10.1158\/1078-0432.CCR-21-2031","article-title":"Risk factors associated with durable progression-Free survival in patients with relapsed or refractory multiple myeloma treated with Anti-BCMA CAR T-cell therapy","volume":"27","author":"Zhang","year":"2021","journal-title":"Clin Cancer Res"},{"key":"key20250730121709_b37-ol-29-5-14999","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/hon.2958","article-title":"Efficacy and follow-up of humanized anti-BCMA CAR-T-cell therapy in relapsed\/refractory multiple myeloma patients with extramedullary-extraosseous, extramedullary-bone related, and without extramedullary disease","volume":"40","author":"Li","year":"2022","journal-title":"Hematol Oncol"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T09:17:18Z","timestamp":1753867038000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2025.14999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":37,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3,28]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2025.14999","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"type":"print","value":"1792-1074"},{"type":"electronic","value":"1792-1082"}],"subject":[],"published":{"date-parts":[[2025,3,28]]}}}